In a major relief for multiple sclerosis (MS) patients across the European Union, the European Medicines Agency (EMA) is expected to give its nod for a pill that could be twice as effective as the current injections.
While the pill, known as Gilenya which is manufactured by Novartis, is available in the US and Russian markets, the only respite for European MS patients are injections. However the latest recommendation by the EMA will come as a big relief since the pill is not only less painful, but is also more effective than some of the popular injections available to treat the condition.
However the EMA has recommended that the pill should be made available for only those patients suffering from active relapsing-remitting multiple sclerosis (RRMS) or those who fail to respond positively to the interferon beta injection.
"The availability of a tablet to treat the condition will give people more choice and for many will come as a welcome relief from frequent injections", policy and research director of the MS Society, Dr Jayne Spink said.